Skip to main content

Table 1 Clinical characteristics of the patients

From: Sema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase

 Sema4A high (≥ 2500 U/ml) (n = 63)Sema4A low (< 2500 U/ml) (n = 138)P
Female/male (% female)51/12 (81.0)112/26 (81.2)0.972
Age at onset (mean ± SD, years)28.8 ± 8.434.8 ± 9.70.00004*
Disease duration from onset to examination (mean ± SD, years)6.3 ± 8.58.1 ± 6.90.125
Sema4A (mean ± SD, U/mL)26,003.7 ± 108,879.5439.9 ± 635.2
Positive ratio of OCB (n/N, (%))29/46 (63.0)54/104 (51.9)0.207
Distribution of MRI lesions (n/N, (%))
 - Cerebrum59/62 (95.2)129/138 (93.5)0.643
 - Cerebellum10/60 (16.7)25/138 (18.1)0.806
 - Brain stem27/62 (43.5)72/138 (52.2)0.259
 - Spinal cord45/61 (73.8)93/137 (67.9)0.405
 - Optic nerve22/61 (36.1)45/136 (33.1)0.683
EDSS change before Sema4A analysis (mean ± SD, /year)0.7 ± 0.50.4 ± 0.50.01*
ARR before Sema4A analysis (mean ± SD, /year)1.13 ± 0.940.83 ± 0.740.04*